leadf
logo-loader
viewKintara Therapeutics
(
NASDAQ:KTRA
)

Kintara Therapeutics' Phase 2 topline results to treat GBM shows 'improvement over standard of care'

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) CEO Saiid Zarrabian tells Proactive the group has reported topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083.

Zarrabian says the Phase 2 trial testing VAL-083 in glioblastoma multiforme (GBM) patients was 'encouraging' as it 'showed an 'improvement over the standard of care.'

Quick facts: Kintara Therapeutics

Follow
NASDAQ:KTRA

Price: 0.88 USD

Market Cap: $28.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Kintara Therapeutics enrolls patients at 26 sites within around 7 months

Kintara Therapeutics (NASDAQ:KTRA) Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites. Zarrabian...

2 weeks, 3 days ago

2 min read